Byoung Young Woo

This inventor holds 14 USPTO granted patents and 5 published patent applications, plus 1 CIPO patent and 9 EPO patents. Top assignee: Amorepacific Corporation. Active years: 2010-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Byoung Young Woo. Retrieved from https://idiyas.com/inventor/byoung-young-woo

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 (Patent Applications = 5)

% Patents Active = 92.9

CIPO Patents = 1

EPO Patents = 9 (Patent Applications = 10)

Average Co-Inventor Count = 10.1

ph-index = 1

Forward Citations = 24(Granted Patents)

Company Filing History:

14 out of 562

Amorepacific Corporation

patents

Years Active: 2010-2024

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12059412 - Pharmaceutical composition containing (R)-N-[1-(3,5-difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethylpyridin-3-yl)-acrylamide and method for inhibiting crystal formation thereof (2024-08-13),

2. 11998633 - Topical sol-gel composition for the treatment of dermatitis (2024-06-04),

3. 11992541 - Nanoemulsion cosmetic composition and process for preparing same (2024-05-28),

4. 11957669 - Pharmaceutical composition containing (R)-N-[1-(3,5-difluoro-4-methansulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide (2024-04-16),

5. 11878008 - Composition for preventing or treating atopic dermatitis (2024-01-23),

6. 11382900 - Composition for preventing or treating sleep disorders (2022-07-12),

7. 10858315 - Method for preparing (R)-N-[4-(1-amino-ethyl)-2,6-difluoro-phenyl]-methanesulfonamide (2020-12-08),

8. 10696611 - Adamantane derivative compound (2020-06-30),

9. 10479763 - Chiral resolution method of N-[4-(1-aminoethyl)-phenyl]-sulfonamide derivatives (2019-11-19),

10. 8691855 - Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist and pharmaceutical compositions containing the same (2014-04-08),

11. 8557872 - Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same (2013-10-15),

12. 8013187 - 2-cyclopenten-1-one oxime derivatives inhibiting production of TNF-α (2011-09-06),

13. 7858621 - Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same (2010-12-28),

14. 7763657 - Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same (2010-07-27),

Title: The Innovative Mind of Byoung Young Woo

Introduction: Byoung Young Woo is a pioneering inventor hailing from Yongin-si, South Korea. His creative spirit and dedication to innovation have led to remarkable contributions in the field of patents and inventions.

Latest Patents: Byoung Young Woo's latest patents showcase his forward-thinking approach to problem-solving and technology. His recent inventions have been recognized for their ingenuity and practical applications in various industries.

Career Highlights: Throughout his illustrious career, Byoung Young Woo has consistently pushed the boundaries of what is possible. His passion for innovation has resulted in numerous groundbreaking inventions that have made a significant impact on the world.

Collaborations: Byoung Young Woo has collaborated with leading experts and organizations in the industry to bring his ideas to life. His ability to work effectively in teams and leverage the expertise of others has been instrumental in the success of his projects.

Conclusion: Byoung Young Woo's relentless pursuit of innovation and his commitment to excellence have established him as a prominent figure in the world of inventors. His remarkable achievements continue to inspire future generations of inventors and innovators.

Profile summary based on public USPTO records.